Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Yun-Gyoo | - |
dc.contributor.author | Kang, Eun Joo | - |
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Choi, Jin-Hyuk | - |
dc.contributor.author | Kim, Jin-Soo | - |
dc.contributor.author | Park, Keon Uk | - |
dc.contributor.author | Lee, Kyoung Eun | - |
dc.contributor.author | Kwon, Jung Hye | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Kim, Min Kyoung | - |
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Shin, Seong Hoon | - |
dc.contributor.author | Kim, Hye Ryun | - |
dc.contributor.author | Kim, Sung-Bae | - |
dc.contributor.author | Yun, Hwan Jung | - |
dc.date.accessioned | 2021-08-30T16:10:00Z | - |
dc.date.available | 2021-08-30T16:10:00Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2020-08-27 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/53725 | - |
dc.description.abstract | BackgroundBy investigating treatment patterns and outcomes in locally advanced head and neck squamous cell carcinoma (LA-HNSCC), we aimed at providing valuable insights into the optimal therapeutic strategy for physicians in real-world practice.MethodsThis is a multi-institutional study enrolled the patients with stage III to IVB LA-HNSCC, except for nasopharyngeal carcinoma, from 2004 to 2015 in thirteen referral hospitals capable of multidisciplinary care.ResultsA total of 445 LA-HNSCC patients were analyzed. The median age was 61years (range, 24-89). The primary tumor location was the oropharynx in 191 (43%), oral cavity in 106 (24%), hypopharynx in 64 (14%), larynx in 57 (13%) and other sites in 27 (6%). The most common stage was T2 in 172 (39%), and N2 in 245 (55%). Based on treatment intents, 229 (52%) of the patients received definitive concurrent chemoradiotherapy (CCRT) and 187 (42%) underwent surgery. Approximately 158 (36%) of the study population received induction chemotherapy (IC). Taken together, 385 (87%) of the patients underwent combined therapeutic modalities. The regimen for definitive CCRT was weekly cisplatin in 58%, 3-weekly cisplatin in 28% and cetuximab in 3%. The preferred regimen for IC was docetaxel with cisplatin in 49%, and docetaxel, cisplatin plus fluorouracil in 27%. With a median follow-up of 39months, one-year and two-year survival rates were 89 and 80%, respectively. Overall survival was not significantly different between CCRT and surgery group (p=0.620).ConclusionsIn patients with LA-HNSCC, the majority of patients received combined therapeutic modalities. Definitive CCRT, IC then definitive CCRT, and surgery followed by adjuvant CCRT or radiotherapy are the preferred multidisciplinary strategies in real-world practice. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.subject | INDUCTION CHEMOTHERAPY | - |
dc.subject | HUMAN-PAPILLOMAVIRUS | - |
dc.subject | NONOROPHARYNGEAL HEAD | - |
dc.subject | CISPLATIN | - |
dc.subject | FLUOROURACIL | - |
dc.subject | DOCETAXEL | - |
dc.subject | SURVIVAL | - |
dc.subject | CANCER | - |
dc.subject | CHEMORADIOTHERAPY | - |
dc.subject | OROPHARYNGEAL | - |
dc.title | Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kang, Eun Joo | - |
dc.identifier.doi | 10.1186/s12885-020-07297-z | - |
dc.identifier.scopusid | 2-s2.0-85090009181 | - |
dc.identifier.wosid | 000567401700001 | - |
dc.identifier.bibliographicCitation | BMC CANCER, v.20, no.1 | - |
dc.relation.isPartOf | BMC CANCER | - |
dc.citation.title | BMC CANCER | - |
dc.citation.volume | 20 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | INDUCTION CHEMOTHERAPY | - |
dc.subject.keywordPlus | HUMAN-PAPILLOMAVIRUS | - |
dc.subject.keywordPlus | NONOROPHARYNGEAL HEAD | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | CHEMORADIOTHERAPY | - |
dc.subject.keywordPlus | OROPHARYNGEAL | - |
dc.subject.keywordAuthor | Locally advanced head and neck cancer | - |
dc.subject.keywordAuthor | Squamous cell carcinoma | - |
dc.subject.keywordAuthor | Multidisciplinary treatment | - |
dc.subject.keywordAuthor | Strategy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.